Fluticasone/formoterol
| Combination of | |
|---|---|
| Fluticasone | Inhaled corticosteroid (ICS) |
| Formoterol | Long-acting beta agonist (LABA) |
| Names | |
| Trade names | Flutiform, Iffeza, others[1][2] |
| Other names | Fluticasone propionate/formoterol fumarate[2] |
| Clinical data | |
| Main uses | Asthma[3] |
| Side effects | Dry mouth, trouble sleeping, rash[1] |
Fluticasone/formoterol, sold under the brand name Flutiform among others, is a combination medication used in the long-term treatment of asthma.[3] It is used by breathing in two puffs of the medication twice per day.[1]
Side effects may include dry mouth, trouble sleeping, rash, cough, and thrush.[1] It contains fluticasone, an inhaled corticosteroid (ICS) and formoterol, a long-acting beta agonist (LABA).[3]
The combination is approved for medical use in a number of countries in Europe in 2012.[2] It is also approved in Australia, South Korea, and Japan.[4] It is on the World Health Organization's List of Essential Medicines as an alternative to budesonide/formoterol.[5] In the United Kingdom 120 doses costs the NHS about £28 as of 2023.[6]
References
- ↑ 1.0 1.1 1.2 1.3 "Fluticasone with formoterol". NICE. Archived from the original on 13 September 2023. Retrieved 10 September 2023.
- ↑ 2.0 2.1 2.2 "Flutiform". European Medicines Agency. 17 September 2018. Archived from the original on 18 April 2021. Retrieved 10 September 2023.
- ↑ 3.0 3.1 3.2 Dissanayake, S; Grothe, B; Kaiser, K (December 2012). "Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma". Respiratory medicine. 106 Suppl 1: S20-8. doi:10.1016/S0954-6111(12)70006-9. PMID 23273163.
- ↑ Prosser, TR; Bollmeier, SG (2015). "Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma". Therapeutics and clinical risk management. 11: 889–99. doi:10.2147/TCRM.S55116. PMID 26082638.
- ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ↑ "Fluticasone with formoterol Medicinal forms". NICE. Archived from the original on 13 September 2023. Retrieved 10 September 2023.
- Pages using duplicate arguments in template calls
- CS1: long volume value
- Chemical articles with unknown parameter in Infobox drug
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- World Health Organization essential medicines (alternatives)
- RTT